Original articleOral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis
Section snippets
Methods
After approval by the Institutional Review Board at Children’s Memorial Hospital/Northwestern University, Chicago, IL, the charts of all 3- to 17-year-old patients for whom the International Classification of Diseases, Ninth Revision code corresponded to focal (705.2) primary hyperhidrosis were systematically reviewed. All patients had been personally evaluated by a board-certified pediatric dermatologist. Patients with hyperhidrosis for less than 6 months or with generalized or secondary
Results
Records for 159 pediatric patients with the diagnosis of hyperhidrosis who were seen between January 2001 and December 2010 were available for review. Of these patients, 31 (19%) were determined to have severe hyperhidrosis at presentation (interfered with activities daily) and had been administered at least one dose of oral glycopyrrolate. All of these pediatric patients were confirmed to have had: (1) at least weekly episodes of excessive sweating during waking hours; (2) involvement in a
Discussion
Hyperhidrosis can be of significant psychosocial concern for older children and adolescents. Over-the-counter and prescription aluminum salts have traditionally been the initial therapeutic choice, but can cause significant irritation. Our experience during the past decade shows excellent efficacy (90%) and a low risk of side effects from the administration of oral glycopyrrolate in pediatric patients with primary focal hyperhidrosis whose response or tolerance to topical application of
References (26)
- et al.
US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey
J Am Acad Dermatol
(2004) - et al.
Recognition, diagnosis, and treatment of primary focal hyperhidrosis
J Am Acad Dermatol
(2004) Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients
J Am Acad Dermatol
(2009)- et al.
Functional analysis of muscarinic acetylcholine receptors using knockout mice
Life Sci
(2004) Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine
J Am Acad Dermatol
(2012)- et al.
Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin
J Am Acad Dermatol
(2002) - et al.
Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety
J Am Acad Dermatol
(2007) - et al.
Intradermal botulinum A toxin injection for axillary hyperhydrosis
J Pediatr Surg
(2005) - et al.
Evidence-based review of the nonsurgical management of hyperhidrosis
Thorac Surg Clin
(2008) - et al.
Thoracoscopic upper thoracic sympathectomy for primary palmar hyperhidrosis in children and adolescents
J Pediatr Surg
(1995)
Palmar hyperhidrosis: long-term follow-up of nine children and adolescents treated with botulinum toxin type A
Pediatr Dermatol
Primary pediatric hyperhidrosis: a review of current treatment options
Pediatr Dermatol
Diagnosis and treatment of primary focal hyperhidrosis in children and adolescents
Semin Cutan Med Surg
Cited by (41)
The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Therapeutic options
2019, Journal of the American Academy of Dermatology
Funding sources: None.
Conflicts of interest: None declared.
Reprints not available from the authors.